drugset / Trial / NCT03999658
A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study evaluates the efficacy, as measured by the objective response rate, of STI-3031, an anti-PD-L1 antibody, in previously treated patients with selected advanced lymphomas or biliary tract cancer.
Timeline
- Start
- 2023-03
- Primary completion
- 2024-01
- Completion
- 2024-07
Outcome
Outcome not reported
Stopped: “Sorrento Therapeutics filed for chapter 11 bankruptcy.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | STI-3031 | Unknown | — | Intravenous |